Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate ...

Novo Nordisk (NVO ... through the legal process and in discussions with the FDA. Compounders and telehealth providers have continued their offerings for both Novo's semaglutide and Eli Lilly's ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

"We look forward to the opportunity to introduce this evidence again through the legal process and in discussions ... was based on a thorough review of Novo Nordisk's stable and growing supply ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...